Woodbridge, CT, United States of America

Brian R Dixon

USPTO Granted Patents = 19 

Average Co-Inventor Count = 4.7

ph-index = 7

Forward Citations = 127(Granted Patents)


Company Filing History:


Years Active: 1998-2005

Loading Chart...
19 patents (USPTO):Explore Patents

Title: Innovations of Brian R. Dixon in Pharmaceutical Compounds

Introduction

Brian R. Dixon, located in Woodbridge, CT, has established a notable presence in the field of pharmaceutical innovations. With a total of 19 patents to his name, Dixon's work primarily focuses on the development of compounds that target critical medical conditions, showcasing his significant contribution to medical science through his inventive spirit.

Latest Patents

Dixon's latest patents include groundbreaking innovations such as the "Inhibition of Matrix Metalloproteases by Substituted Biaryl Oxobutyric Acids." This invention presents matrix metalloprotease inhibiting compounds, pharmaceutical compositions, and methods of treating diseases facilitated by these compounds. The generalized formulas highlight the structure of these compounds, emphasizing their potential in combating various health issues. Conditions such as osteoarthritis, rheumatoid arthritis, septic arthritis, and even tumor metastasis are notably targeted, showcasing the broad impact of his inventions on multiple degenerative and inflammatory diseases.

Additionally, another significant patent is centered on "17-beta-hydroxysteroid dehydrogenase-II inhibitors," further expanding his portfolio in developing key therapeutic agents.

Career Highlights

Throughout his career, Brian R. Dixon has collaborated with prestigious organizations such as Bayer Corporation and Bayer Pharmaceuticals Corporation. His experiences in these esteemed companies have undoubtedly influenced his innovative endeavors and shaped his expertise in pharmaceutical research.

Collaborations

Dixon has worked alongside notable colleagues, including Michael C. VanZandt and David R. Brittelli, contributing to a collaborative environment that fosters innovation. These professional relationships reflect a network of inventors committed to advancing pharmaceutical science through cooperative efforts.

Conclusion

Brian R. Dixon's commitment to innovation in pharmaceutical sciences is evidenced by his numerous patents and successful collaborations. His latest inventions, particularly those aimed at inhibiting matrix metalloproteases, underscore his role in addressing significant health challenges. As Dixon continues to explore new avenues for therapeutic advancements, the potential impact of his work is bound to resonate across the healthcare landscape for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…